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Peroxisome proliferator-activated receptor-γ (PPAR)-γ is a ligand-activated transcriptional factor belonging to steroid receptor
superfamily. PPAR-γ plays a role in both adipocyte diﬀerentiation and tumorigenesis. Up to date, PPAR-γ is expressed in various
cancer tissues, and PPAR-γ ligand induces growth arrest of these cancer cells. In this study, we examined the expression of PPAR-γ
in prostate cancer (PC) and testicular cancer (TC) by RT-PCR and immunohistochemistry, and we also examined the eﬀect of
PPAR-γ ligand in these cells by MTT assay, hoechest staining, and ﬂow cytometry. PPAR-γ expression was signiﬁcantly more ex-
tensive and intense in malignant tissues than in normal tissues. PPAR-γ ligand induced the reduction of malignant cell viability
through apoptosis. These results demonstrated that the generated PPAR-γ in PC and TC cells might play an important role in the
tumorigenesis. PPAR-γ may become a new target in the treatment of PC and TC.
Copyright © 2008 M. Matsuyama and R. Yoshimura. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Prostate cancer (PC) comprises 32% of all cancers in Amer-
ican men and is on the increase worldwide. Because of in-
creased screening, PC is frequently diagnosed at a clinically
localized stage, making it amenable to the therapy. Never-
theless, it remains the second most common cause of can-
cer death in men. These patients generally respond to an-
drogen deprivation therapy, but the vast majority eventu-
ally experience disease progression and become refractory to
sustained hormonal manipulation. Typically, such patients
progress with a rise in their serum prostate-speciﬁc anti-
gen level. Unfortunately, standard therapeutic options at this
stage of disease are limited, and while there has been some
success with chemotherapy for hormone-refractory prostate
cancer patients, the response is generally short lived [1].
Testicularcancer(TC)isveryrarewithover90%ofallTC
being germ cell tumors (seminoma and nonseminoma), and
the remaining percentage nongerminal tumors. The survival
rate of TC has improved in recent years, reﬂecting the devel-
opment and reﬁnementof eﬀectivecombinationchemother-
apy. However, it is still necessary to improve the treatment of
TC.
Angiogenetic factors play an important role in prostate
andtestisasinotherorgans[2],andalthoughvariouspoten-
tial angiogenetic factors have been identiﬁed in PC and TC,
it is still unclear by which process PC and TC cells become
angiogenic. Thus, the challenge is to discover new treatment
strategies that target androgen-independent PC and TC. The
identiﬁcation of molecular targets involved in the tumorige-
nesis and progression of PC and TC provide opportunities
for the development of new agents with greater therapeutic
potential and better speciﬁcity. Patients with advanced or re-
currentdiseasearesuitablecandidatesforstudiesthattestthe
eﬃcacy of these new agents.
Peroxisome proliferator-activated receptors (PPARs) are
lipid-activated transcription factors that function as impor-
tant regulars of lipid and glucose metabolism, adipocyte dif-
ferentiation, and energy homeostasis. PPAR subtypes (α, β,
and γ) have been found. Both PPAR-α and -γ mediate the2 PPAR Research
action of the hypolipidemic ﬁbrates and antidiabetic thiazo-
lidinediones. PPARs therefore play a role in metabolic con-
ditions such as dyslipidemia and type 2 diabetes, leading to
atherosclerosis development [3]. PPARs also have regulatory
role in inﬂammation.
PPAR-γ provides a strong link between lipid metabolism
and regulation of gene transcription [4]. PPAR-γ acts in adi-
pose tissue and promotes lipogenesis under anabolic con-
ditions. Recently, the receptor has also been implicated in
inﬂammation and tumorigenesis. Signiﬁcant evidence from
many experimental systems suggests that PPAR-γ is impor-
tant in carcinogenesis.
PPAR-γ is up regulated in malignant tissue, and PPAR-
γ ligands induce terminal diﬀerentiation in human breast
and colon cancer cells [5, 6], and inhibit the growth of
human lung and gastric cancer cells [7, 8]. In addition,
PPAR-γ ligands induce growth arrest through apoptosis in
macropharge, ﬁbrobrasts, and endothelial cells [3, 9, 10].
Our research elucidates the expression of PPARs in urolog-
ical cancers and administration of PPAR-γ ligands as an an-
ticancer therapy [11–15]. Several reports support the expres-
sionofPPAR-γ andtheeﬃcacyofPPAR-γ ligandsinPC[16–
18]. However, no further data on TC and PPAR-γ have been
documented in other reports.
Our research focuses on the relationship between PPAR-
γ and male reproductive system (prostate and testis) and on
the anticancer eﬀect of PPAR-γ ligands.
2. METHODS
2.1. Tumorspecimens
Prostate specimens were obtained from 156 patients with
PC; 15 with prostatic intraepithelial neoplasia (PIN); 20 with
benign prostatic hyperplasia (BPH), who underwent biopsy
due to serum prostate-speciﬁc antigen increase; and 12 pa-
tients with normal prostate (NP) tissues who underwent to-
tal cystectomy due to bladder cancer.
Testis specimens were obtained from 72 TC patients, and
from 20 NT patients who underwent orchiectomy for PC.
Tumor tissues, nontumor tissues, vascular endothelium, and
interstitial tissues from the subjects were preserved in 10%
formalin and embedded in paraﬃn, serially sectioned onto
microscope slides at a thickness of 4μm.
2.2. Antibodies
PPAR-α,- β,a n d- γ are aﬃnity-puriﬁed goat polyclonal an-
tibodies. We purchased these antibodies from Santa Cruz
Biotechnology Inc (Santa Cruz, Calif, USA). They demon-
strated about the source of these antibodies, PPAR-α and -γ
are aﬃnity-puriﬁed goat polyclonal antibodies raised against
a peptide mapping at the amino terminus of PPAR-α and
-γ of human origin (α diﬀers from corresponding mouse
sequence by amino acids; γ is identical to the correspond-
ing mouse sequence). PPAR-β is an aﬃnity-puriﬁed goat
polyclonal antibody raised against a peptide mapping at the
carboxy terminus of PPAR-β of human origin (diﬀers from
corresponding mouse sequence by two amino acids). About
speciﬁcity of these antibodies, PPAR-α and -β react with
those of mouse, rat and human origin by Western blotting
and immunohistochemistry. PPAR-γ also reacts with PPAR-
γ1andPPAR-γ2ofmouse,rat,andhumanoriginb yW est ern
blotting and immunohistochemistry. These speciﬁc antibod-
ies do not cross-match either each other, nor do they cross-
react with each other.
2.3. RT-PCR
Total RNA was isolated from PC tissues, BPH and NP tissues
(freshtissues)byguanidiumthiocyanate-phenol-chloroform
method. We performed an RT-PCR procedure to determine
the PPAR-α,- β,a n d- γ mRNA expression as described pre-
viously [19]. In short, total RNA was used as a template for
DNA synthesis using a superscript preampliﬁcation system
(GIBCO-BRL) according to the manufacturer instructions.
PCR was performed with each cDNA; PPAR-α,- β,a n d-
γ; or G3PDH primer and Taq DNA polymerase (NIPPON
GENE, Toyama, Japan). The synthetic oligonucleotides were
obtained from Nippon Flour Mills (Kanazawa, Japan). We
used G3PDH mRNA as a control.
The primers used were as follows:
(a) PPAR-α:s e n s e ;5  -CCAGTATTTAGGACGCTGTCC-
3  and antisense 5 -AAGTTCTTCAAGTAGGCCA-
GC-3 ;
(b) PPAR-β:s e n s e ;5  -AACTGCAGATGGGCTGTAAC-3 
and antisense 5 -GTCTCGATGTCGTGGATCAC-3 ;
(c) PPAR-γ:s e n s e ;5  -TCTCTCCGTAATGGAAGACC-3 
and antisense 5 -GCATTATGAGACATCCCCAC-3 ;
(d) human G3PDH: sense; 5 -CCACCCATGGCAAATT-
CCATGGCA-3  and antisense; 5 -TCTAGAGGGC-
AGGTCAGGTCCACC-3 .
The primer sets yield PCR products of 492, 484, 474, and
598 base pair for PPAR-α,- β,a n d- γ or G3PDH, respec-
tively. Reactions were incubated in an automatic heat-block
for30cyclesofdenaturation40seconds,94
◦C;annealing for
50 seconds, 50
◦C; extension for 50 seconds, 72
◦C[ 19]. PCR
products were run on 2% agarose gel in TAE buﬀer (40mM
Tris acetate, 1mM EDTA) and visualized by ethidium bro-
mide staining.
2.4. Immunohistochemistry
Tissues sections (4μm thick) were incubated with anti-
PPAR-α,- β,a n d- γ antibody (2μg/mL) or puriﬁed nor-
mal goat IgG (2μg/mL) in a humid chamber for 24 hours,
and further incubated with biotinylated rabbit antigoat IgG
(Vector Laboratories, Inc. Burlingame, Calif, USA) for 30
minutes. After washing with PBS, the sections were incu-
bated with the vectastatin avidin-biotin peroxidase com-
plex kit (Vector, Burlingame, Calif, USA) [20] for 45 min-
utes. Color was developed by immersing the sections in a
solutions of 0.05% wt/vol 3, 3 -diaminobenzidine tetrahy-
drochloride (Sigma-Aldrich, St. Louis, Mo, USA). The sec-
tions were counterstained with hematoxylin (Sigma-Aldrich,
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2.5. Statisticalanalysis
The extent and intensity of staining with PPAR-α,- β,a n d
-γ antibodies were graded on a scale of 0 to 4 (+) by two
blind observers on two separate occasions using coded slides,
and an average score was calculated [21]. Staining was clas-
siﬁed into 5 grades from 0 to 4 (+) according to the inten-
sity of staining and the number of positive cells. The ob-
servers assessed all tissues on the slides to assign the score. A
4 (+) grade implies that all staining was maximally intense
throughout the specimen, whereas 0 implies that staining
was absent throughout the specimen. The microanatomical
sites of staining were also recorded. To quantify the expres-
sions of PPAR-α,- β,a n d- γ, the same two pathologists made
assessments throughout the study, staining control speci-
mens simultaneously. This method, therefore, increases the
credibility ofdata. Inaddition, allspecimenswerereassessed,
which also contributed to the exclusion of any subjective
variability.
2.6. Cellcultures
The human PC cell lines (LNCaP, PC3, DU-145) and TC
cell line (NEC-8) were obtained from Health Science Re-
search Resources Bank (Osaka, Japan). Cells were grown
in culture ﬂask (Nunc, Roskilde, Denmark) in RPMI 1640
supplemented with 10% FBS, 100U/mL of penicillin and
100μg/mL of streptomycin in a humidiﬁed 5% CO2 atmo-
sphereat37
◦C.Themediawerechangedevery3daysandthe
cells were separated via trypsinization, using trypsin/EDTA
when they reached subconﬂuence.
2.7. Cellproliferativestudies
Troglitazone (thiazolidinedione compounds) was obtained
from Sankyo Pharmaceuticals (Tokyo, Japan). 15-deoxy-
Δ12,14-prostaglandin J2 (15-d-PGJ2) was purchased from
Cayman Chemical Company (St. Louis, Mo, USA). GW9662
was purchased from BIOMOL Research Laboratories Inc.
(Pa, USA). Approximately 1.0 × 104 cells (all PC and TC
cell lines) placed onto 8 × 8mm diameter multichamber
slides (Nunc, Copenhagen, Denmark) were treated with
troglitazone and 15-d-PGJ2 (5–40μM) dissolved in ethanol.
The ﬁnal concentration of ethanol was <0.05%. Cell via-
bility was measured after 48 hours by a microplate reader
using a modiﬁed 3-[4,5-dimethylthiazol-2-thiazolyl]-2,5-
diphenyltetrazolium bromide (MTT) assay (WST-1 assay;
Dojindo, Kumamoto, Japan) and presented as the percent-
age of control-culture conditions (N = 6).
2.8. Flowcytometry(annexinVand
propidiumiodidestaining)
The eﬀects of PPAR-γ ligands on PC (PC3) and TC (NEC-
8) cell lines were determined by dual staining with Annexin
V-FITC and propidium iodide using Annexin V-FITC Apop-
tosis Detection Kit I (Biosciences Pharmingen, Calif, USA).
Annexin V-FITC and propidium iodide (PI) were added to
the cellular suspension as in the manufacturer instruction,
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Figure 1: RT-PCR analysis of PPAR-α,- β, and -γ in prostate tis-
sue samples from the patients with PC, PIN, BPH and NP. A slight,
but clear, band of PPAR-α and -β m-RNA was detected in all sam-
ples. However, the speciﬁc band of PPAR-γ mRNA in the samples
from prostate cancer (PC) and prostatic intraepithelial neoplasia
(PIN) was detected, while samples from benign prostatic hyperpla-
sia (BPH) displayed a very weak band, and in a sample from normal
prostate (NP) no clear band was detected.
and sample ﬂuorescence of 1.0 × 104 cells was analyzed ﬂow
cytometry. Flow cytometry was with FACScan (Becton Dick-
inson, Heidelberg, Germany). Cell which were Annexin V-
FITCpositiveandPInegativewereidentiﬁedasearlyapopto-
sis. Cell which were Annexin V-FITC positive and PI positive
were identiﬁed as late apoptosis or necrosis.
2.9. Flowcytometry(identiﬁcationof
DNAfragmentation)
The assay was performed by TdT-mediated dUTP Nick End
Labelling (TUNEL) method using APO-DIRECT kit (Bec-
ton Dickinson). Following the experiments, PC (PC3) and
TC (NEC-8) cell lines in suspension (1×106/mL) were ﬁxed
with 1% PBS, washed in PBS, and suspended in 70% (v/v)
ice-cold ethanol. The cells were stored in ethanol at −20
◦C
until use. The positive and negative controls and the sam-
ple were stained with FITC-dUTP by incubation in termi-
nal deoxynucleotidyl transferase buﬀer as in the manufac-
turer instruction, and sample ﬂuorescence of 1 × 104 cells4 PPAR Research
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Figure 2: Representative immunostaining for PPAR-γ in prostate tissues samples. A signiﬁcant strong PPAR-γ expression in all prostate
cancer (PC) group tissues and prostatic intraepithelial neoplasia (PIN) tissue was detected, whereas PPAR-γ expression is very weak in
benign prostatic hyperplasia (BPH) tissues and normal prostate (NP) tissue.
was analyzed by ﬂow cytometry (Becton Dickinson). Results
are given as % of TUNEL-positive cells.
2.10. DetectionofapoptosisbyHoechststaining
DNA chromatin morphology was assessed using Hoechst
staining. PC (PC3) and TC (NEC-8) cell (5 × 105 cells) were
incubated with 20μMP P A R - γ ligands for 24 hours. Cells
were washed by RPMI-1640 and labeled with 8mg/mL of
hoechest 33342 (Sigma-Aldrich Japan K.K. Tokyo, Japan) for
10 minutes; PI (Sigma-Aldrich Japan K.K. Tokyo, Japan) was
added (10mg/mL ﬁnal concentration), and the cells were ex-
amined by ﬂuorescence microscopy.
2.11. Statisticalanalysis
All results are presented as the mean ± SD. Analysis of data
was performed using the analysis of variance (ANOVA) [22].
3. RESULTS
3.1. Tumorspecimens
3.1.1. PCtissuesample
The 156 patients with PC were male aged 59–78 years (mean
age 67 ± 5.3 years). We used Gleason score to evaluate PC.
Gleason score is given to PC based upon its microscopic ap-
pearance.GleasonscoreisimportantbecausehigherGleason
scores are associated with worse prognosis. This is because
higher Gleason scores are given to cancer which is more ag-
gressive. Gleason score ranges from 2 to 10. Gleason score
of 2 is associated with the best prognosis and a score of 10
with the worst. The ﬁnal score is a combination of two dif-
ferent scores which each range from 1 to 5. Gleason score is
as follows: low group: Gleason score, 2, 3, 4, 5, middle group:
G l e a s o ns c o r e ,6 ,7 ,8 ,h i g hg r o u p :G l e a s o ns c o r e ,9 ,1 0 .I n
clinical PC, Gleason score is almost over 5.M. Matsuyama and R. Yoshimura 5
(a) Seminoma (b) Embryonal carcinoma
(c) Yolk sac tumors (d) Choriocarcinoma
(e) Teratoma (f) Nomal testis
Figure 3: Representative immunostaining for PPAR-γ in testicular tissues samples. A signiﬁcant strong PPAR-γ expression in all testicular
cancer (TC) tissues was detected, whereas PPAR-γ expression is very weak in normal testis (NT) tissues.
The 50 patients were in the low group, 54 were in the
middlegroup,and52wereinthehighgroup.The15patients
with PIN averaged 64 ± 5.9 (52–73) years. The 20 patients
with BPH averaged 68±4.7 years (59–75), and all had nodu-
lar hyperplasia. The 12 patients with NP averaged 52 ± 7.6
(44–62) years.
3.1.2. TCtissuesample
The 72 TC patients were a mean age of 31.0 ± 12.3y e a r s .
Tumors of single histologic types were found in 58 patients
and more than two histological types in 14 patients. Semi-
noma occurred in 31 patients, embryonal carcinoma in 8 pa-
tients, yolk sac tumor in 7 patients, choriocarcinoma in 7 pa-
tients, and teratoma in 5 patients. Tumors having more than
two histologic types included embryonal carcinoma and ter-
atoma in 4 patients, choriocarcinoma and other types in 3
patients, and other combinations in 7 patients. The average
age of 20 patients NT tissues was 61.4 ±8.6y e a r s .
3.2. RT-PCR
To check PPAR-α,- β,a n d- γ mRNA variation, RT-PCR was
performed with total RNA extracted from all specimens. Us-
ing speciﬁc primers for PPAR-α,- β,a n d- γ and G3PDH, the
ampliﬁcation predicted, respectively, fragments of 492, 484,
474, and 598 base pair (bp) in length.
3.2.1. PCtissuesample
The PPAR-α and -β mRNA were detected in PC, PIN, BPH,
and NP samples. However, we detected a speciﬁc band of
PPAR-γ mRNA in the samples from PIN and PC, and we
also detected a very weak speciﬁc band of PPAR-γ mRNA in6 PPAR Research
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Figure 4: Eﬀects of PPAR-γ ligands on apoptosis by ﬂow cytometry in PC and TC cell lines. PC cells (PC3) and TC cell (NEC-8) lines
with treatment of 25μM 15-d-PGJ2 could induce early apoptosis not late apoptosis or necrosis. The higher left quadrants represent early
apoptosis (Annexin V-FITC-positive cells and PI-negative cells). The higher right quadrants represent late apoptosis or necrosis (Annexin
V-FITC-positive cells and PI-positive cells). Diagrams of FITC-Annexin V/PI ﬂow cytometry are presented.
thesamplefromBPH,whereassamplefromNP displayed no
band of PPAR-γ mRNA (see Figure 1).
3.2.2. TCtissuesample
The PPAR-α and -β mRNA were detected in all TC and NT
samples. However, we detected a speciﬁc band of PPAR-γ
mRNA in all TC groups, whereas sample from NT displayed
no band of PPAR-γ mRNA.
3.3. ImmnohistostainingofPPAR-α,-β,and-γ
To assess the tissue distribution of PPAR-α,- β,a n d- γ
polypeptides, we stained paraﬃn-embedded samples with
the aﬃnity-puriﬁed PPAR-α,- β,a n d- γ antibodies that rec-
ognize speciﬁcally PPAR-α,- β,a n d- γ. The speciﬁcity of this
antibody was proved by the previous experiments [23].
3.3.1. PCtissuesample
PPAR-α,a n d- β were expressed in PC, PIN, BPH, and NP
tissues. Although very weak expression of PPAR-γ was found
in BPH and NP tissues, PPAR-γ was strongly expressed in all
PC groups and PIN (see Figure 2).
3.3.2. TCtissuesample
PPAR-α,a n d- β were expressed in all TC and NT tissues.
Although no expression of PPAR-γ was found in NT tis-
sues, PPAR-γ was strongly expressed in all TC groups (see
Figure 3).M. Matsuyama and R. Yoshimura 7
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Figure 5: PPAR-γ ligands induce DNA fragmentation in PC and TC cell lines. 15-d-PGJ2 (2μM) could induce DNA fragmentation in PC
cell (PC3) and TC cell line (NEC-8). Typical ﬂow cytometry analysis histograms are presented.
3.4. StatisticalanalysisofPPAR-α,-β,and-γ
immunostaining
To extent and intensity of staining with PPAR-α,- β,a n d- γ,
antibody was graded 0 to 4 (+) by 2 blind observers.
3.4.1. PCtissuesample
PPAR-α,- β immunostaining were signiﬁcantly intense in all
cases. There were no diﬀerences among PC, PIN, BPH, and
NP. There was no signiﬁcant diﬀerence of the intensity of
PPAR-α,- β staining between PC, PIN, BPH, and NP. How-
ever, PPAR-γ immunostaining was signiﬁcantly more exten-
sive and intense in tumor cells (mean: low group; 2.6 ± 0.7,
middlegroup;2.7±0.9, highgroup;3.3±1.0, P<. 01)andin
PIN (mean: 2.5 ± 0.8, P<. 01) than in tissue of BPH (mean:
0.8 ± 0.6). PPAR-γ staining was also high in blood vessels
and stromal tissues of prostate cancer and PIN, with no sig-
niﬁcant diﬀerence between them (1.8–2.0). However, the ex-
pression of the PPAR-γ in the blood vessels and stromal tis-
sues from BPH and NP was at the basic level (0.5–0.7) (see
Table 1).
3.4.2. TCtissuesample
PPAR-α,- β immunostaining were signiﬁcantly intense in all
TC groups and NT. However, PPAR-γ immunostaining was
signiﬁcantly more extensive and intense in tumor cells and
blood vessels of the TC groups than in NT. There was no sig-
niﬁcant diﬀerences occurred between all TC group in tumor
cells and blood vessels (see Table 2).
3.5. PPAR-γ ligandsinducedgrowthinhibitionin
PCandTCcelllinesbyMTTassay
To investigate the eﬀects of PPAR-γ ligands on all PC
(LNCaP, PC3, DU-145) and TC cell (NEC-8) lines prolifer-
ation, we analyzed cell viability in vitro by modiﬁed MTT
assay.
3.5.1. PCcellline
PPAR-γ ligands induced the reduction of cell viability with
the half-maximal concentration of growth inhibition of all
PC cell lines (LNCaP, PC3, DU-145) in the range of 5–40μM
(see Table 3). PPAR-γ ligands stopped the growth of all PC
cell lines.
3.5.2. TCcellline
Similar to PC cell lines, PPAR-γ ligands induced the reduc-
tion of cell viability with the half-maximal concentration of
growth inhibition of TC cell line (NEC-8) in the range of8 PPAR Research
Table 1: Statistical analysis of PPAR-α,- β, and -γ immunostaining.
Tumor Blood vessel Stromal tissue
PPAR-α
PC (N = 156)
Low group N = 50) 2.2 ±0.62 .0 ±0.92 .0 ±0.9
Middle group N = 54) 2.4 ±0.72 .3 ±0.71 .9 ±0.6
High group N = 52) 2.3 ±0.71 .9 ±0.62 .0 ±0.8
PIN (N = 15) 1.9 ±0.61 .8 ±0.61 .7 ±0.7
BPH (N = 20) 2.1 ±0.61 .7 ±0.51 .7 ±0.5
NP (N = 12) Not present 2.1 ±0.72 .2 ±1.1
PPAR-β
PC (N = 156)
Low group N = 50) 2.0 ±1.01 .7 ±0.71 .9 ±0.6
Middle group N = 54) 2.3 ±1.21 .6 ±0.71 .8 ±0.7
High group N = 52) 2.1 ±1.01 .7 ±0.61 .8 ±0.9
PIN (N = 15) 2.2 ±0.81 .8 ±0.91 .8 ±0.7
BPH (N = 20) 2.0 ±0.71 .9 ±0.81 .6 ±0.7
NP (N = 12) Not present 1.9 ±0.71 .9 ±0.8
PPAR-γ
PC (N = 156)
Low group N = 50) 2.6 ±0.7∗ 1.8 ±0.9∗ 1.8 ±0.7∗
Middle group N = 54) 2.7 ±0.9∗ 1.8 ±0.8∗ 1.9 ±0.9∗
High group N = 52) 3.3 ±1.0∗ 2.0 ±0.8∗ 1.7 ±0.9∗
PIN (N = 15) 2.5 ±0.8∗ 1.9 ±0.8∗ 1.7 ±0.9∗
BPH (N = 20) 0.8 ±0.60 .6 ±0.50 .7 ±0.5
NP (N = 12) Not present 0.5 ±0.40 .5 ±0.3
∗Graded 0–4 on the coded sections by two blind observers. 0, no staining; 4+, maximum intensity. Statistical analysis was performed using the ANOVA (p-
value). PPAR-α and -β immunostaining were signiﬁcantly intense in all cases. There were no diﬀernces among PC, PIN, BPH and NP. PPAR-γ immunostain-
ings of tumor were signiﬁcantly more extensive and intense in PC and in PIN than in tissue of BPH or NP. PPAR-γ staining was high in blood vessels and
stromal tissues of PC and PIN, with no signiﬁcant diﬀerence between them. However, the expressions of the PPAR-γ in the blood vessels and stromal tissues
from BPH and NP were at the basic level. (∗P<. 01).
5–40μM (see Table 3). PPAR-γ ligands stopped the growth
of TC cell line (NEC-8).
3.6. PPAR-γ ligandsinducedapoptosisby
ﬂowcytometry
To evaluate whether or not cell death induced by PPAR-γ
ligands was through apoptosis, we evaluated using ﬂow cy-
tometry. The higher left quadrants represent early apoptosis
(Annexin V-FITC-positive cells and PI-negative cells). The
higher right quadrants represent late apoptosis or necrosis
(Annexin V-FITC-positive cells and PI-positive cells).
3.6.1. PCcellline
PC cell line (PC3) with treatment of 25μMP P A R - γ ligand
(15-d-PGJ2) could induce early apoptosis, not late apopto-
sis or necrosis (see Figure 4) and DNA fragmentation (see
Figure 5). Diagrams of FITC-Annexin V/PI ﬂow cytometry
and typical ﬂow cytometry analysis histogram are presented.
3.6.2. TCcellline
TC cell line (NEC-8) with treatment of 25μMP P A R - γ lig-
ands(15-d-PGJ2)couldinduceearlyapoptosisnotlateapop-
tosis or necrosis (see Figure 4) and DNA fragmentation (see
Figure 5). Diagrams of FITC-Annexin V/PI ﬂow cytometry
and typical ﬂow cytometry analysis histogram are presented.
3.7. EffectofPPAR-γ ligandsininductionof
apoptosisonPCandTCcelllines
To evaluate whether or not cell death induced by PPAR-γ
ligands was through apoptosis, we evaluated the chromatin
morphology of PC (PC3) cell and TC cell (NEC-8) lines us-
ing hoechst staining.
3.7.1. PCcellline
PC cell line (PC3) treated with PPAR-γ ligands showed sig-
niﬁcant chromatin condensation, cellular shrinkage, small
membrane-bound bodies (apoptotic bodies), and cytoplas-
mic condensation. These cellular changes were typically re-
dundant characteristics of apoptosis. PC cell lines (PC3)
without PPAR-γ ligands maintained normal chromatin pat-
terns and cell size (see Figure 6). Typical photographs are
presented in Figure 6.
3.7.2. TCcellline
Similar to PC cell line, TC cell line (NEC-8) treated with
PPAR-γ ligands showed signiﬁcant chromatin condensation,M. Matsuyama and R. Yoshimura 9
Table 2: Statistical analysis of PPAR-α,- β, and -γ immunostaining.
Av.± SD
Tumor type Epithelium Blood vessel
PPAR-α
Seminoma (N = 34) 2.2 ±0.81 .7 ±0.9
Embryonal carcinoma (N = 15) 2.4 ±1.12 .1 ±1.0
Yolk sac tumor (N = 11) 1.8 ±1.01 .6 ±0.7
Choriocarcinoma (N = 10) 2.5 ±1.22 .0 ±0.9
Teratoma (N = 12) 1.8 ±0.91 .6 ±0.9
Normal testis (N = 20) 2.5 ±1.12 .1 ±0.9
PPAR-β
Seminoma (N = 34) 2.4 ±0.92 .2 ±1.1
Embryonal carcinoma (N = 15) 2.6 ±1.42 .3 ±1.2
Yolk sac tumor (N = 11) 2.5 ±1.42 .1 ±0.6
Choriocarcinoma (N = 10) 2.2 ±1.01 .9 ±0.9
Teratoma (N = 12) 2.4 ±0.92 .2 ±1.3
Normal testis (N = 20) 2.5 ±1.12 .3 ±1.0
PPAR-γ
Seminoma (N = 34) 2.2 ±0.8∗ 1.9 ±0.9∗
Embryonal carcinoma (N = 15) 2.8 ±1.1∗ 2.5 ±1.0∗
Yolk sac tumor (N = 11) 2.2 ±0.9∗ 2.1 ±1.1∗
Choriocarcinoma (N = 10) 2.9 ±1.0∗ 2.4 ±1.0∗
Teratoma (N = 12) 2.0 ±1.3∗ 1.9 ±1.1∗
Normal testis (N = 20) 0.7 ±0.60 .6 ±0.4
∗Graded 0 to 4 on the coded sections by two blind observers. 0, no staining; 4+, maximum intensity. Statistical analysis was performed using the analysiso f
variance (P value; ANOVA). PPAR-α,a n d- β immunostaining were signiﬁcanty apparent in all TC and NT tissues. PPAR-γ immunostaining of tumor was
signiﬁcantly more extensive and intense in all TC groups than in NT tissue. PPAR-γ staining was high in blood vesseld of TC, with no signiﬁcant diﬀerence
between them. However, the expression of PPAR-γ in blood vessels from NT was at the basic level. P<. 01.
Table 3: Eﬀects of troglitazone, 15-d-PGJ2 and GW9662 in viabity of human PC and TC cell lines.
5μM1 0 μM2 0 μM4 0 μM
Troglitazone
PC cell lines
LNCaP 72.4% 25.7% 12.6% 8.4%
PC3 48.6% 15.5% 14.7% 6.5%
DU-145 60.1% 35.1% 7.6% 7.7%
TC cell line NEC-8 38.7% 35.3% 36.6% 38.1%
15-d-PGJ2
PC cell lines
LNCaP 78.9% 63.7% 22.4% 5.6%
PC3 69.7% 59.0% 34.1% 6.8%
DU-145 73.8% 59.3% 5.8% 5.8%
TC cell line NEC-8 75.1% 66.7% 52.3% 46.8%
GW9662
PC cell lines
LNCaP 106.8% 112.4% 103.7% 106.2%
PC3 116.8% 118.6% 119.4% 120.2%
DU-145 122.6% 119.4% 117.8% 115.6%
TC cell line NEC-8 108.4% 115.5% 110.6% 112.3%
The dose-response analysis of viability in human cancer cells treated with troglitazone, 15-d-PGJ2 and GW9662 (5–40μM, 48hr) was measured by the MTT
assay and expressed as % of control culture conditions (N = 6).
cellular shrinkage, small membrane-bound bodies (apop-
totic bodies), and cytoplasmic condensation. These cellular
changes were typically redundant characteristics of apopto-
sis. TC cell line without PPAR-γ ligands maintained normal
chromatin patterns and cell size.
4. DISCUSSION
PPAR-αishighlyexpressedintheliver,heart,kidney,muscle,
brown adipose tissue, and gut, which exhibit high carbolic
rates of fatty acid. PPAR-β may be expressed ubiquitously10 PPAR Research
(a)
(b)
(c)
Apoptotic body
Figure 6: Eﬀects of PPAR-γ ligands in induction of apoptosis on
human PC cell line. PC cell line (PC3) treated with PPAR-γ ligands
((b); 20μM Troglitazone, (c); 20μM 15-d-PGJ2) showed signiﬁ-
cant chromatin condensation, cellular shrinkage, small membrane-
bound bodies (apoptotic bodies), and cytoplasmic condensation.
These cellular changes were typically redundant characteristics of
apoptosis. PC cells without PPAR-γ ligands maintained normal
chromatin patterns and cell size (a). Typical photographs are pre-
sented.
and its function is relatively unknown. Recent studies sug-
gestthatPPAR-β maybeatargetfornonsteroidalantiinﬂam-
matory drugs (NSAIDs)-induced tumor suppression in col-
orectal tumors. PPAR-γ is expressed at high level in adipose
tissue and is a critical regulator of adipocyte diﬀerentiation.
In addition, PPAR-α,a n d- γ have been considered important
immunomodulatory factors. PPAR-α knockout mice exhibit
exacerbated inﬂammatory responses, and leukotriene B4,a
chemotractic mediator, appears to regulate the clearance of
itself as an agonist of PPAR-α.H o w e v e r ,P P A R - γ is also ex-
pressed in the immune system, in the spleen monocytes,
bone-marrow precursors, and helper T-cell clones. PPAR-
γ is also expressed in chondrocytes as well as in synovial
and bone tissues. Recent data have shown that PPAR-γ lig-
ands lead to inhibition of phorbol ester-induced nitric oxide
and macropharge-derived cytokines such as tumor necrosis
factor-α (TNF-α), interleukin-1β (IL-1β) and interleukin-6
(IL-6), chemokines, and adhesion molecules, in part by an-
tagonizing the activities of transcriptional factors [7].
Recently, it has been evidenced that thiazolidinedione,
a new class of antidiabetic as a speciﬁc ligand for PPAR-γ,
and retinoic receptor agonists can regulate diﬀerentiation of
cancer cells [24], and that nuclear-acting prostanoids, in-
cluding 15-d-PGJ2, are potent activators of the PPAR-γ re-
ceptor isoform [25, 26]. In fact, 15-d-PDJ2 induces apop-
tosis in macropharge, endothelial cell, choriocarcinoma cell
[3, 10, 27], as well as thiazolidinediones-induced ﬁbroblast
apoptosis [9]. PPAR-γ ligands also inhibit vascular endothe-
lial cell growth factor-induced angiogenesis in vivo [28]. An-
giogenesis is important for tumorigenesis. Antiangiogenetic
therapy is highly promising since it does not induce aquired
anticancerdrugresistance[29,30].Drevsetal.demonstrated
the eﬀect of PTK787/ZK 222584, a speciﬁc inhibitor of vas-
cular endothelial growth factor receptor tyrosine kinases, on
primary tumor, metastasis, vessel density, and blood ﬂow
in an animal model of renal cell carcinoma [31]. PPAR-
γ agonists induce apoptosis in endothelial cells and inhibit
vascular endothelial growth factor-induced angiogenesis in
rats. Therefore, PPAR-γ ligands may have anticancer eﬀects
through inhibition of cell proliferation and angiogenesis.
In this time, concerning about PC, we demonstrated a
stronger expression of PPAR-γ in PC and PIN tissues than
in BPH or NP tissues by immunohistochemical staining and
RT-PCR. We classiﬁed 3 categories (epithelial cells, blood
vessels, and stromal tissues) in PC, PIN, BPH, and NP tis-
sues, and examined the intensity of PPAR-α,- β,a n d- γ ex-
pressions in all tissue categories. There were no signiﬁcant
diﬀerences in the intensity of PPAR-α and -β in PC, PIN,
BPH, and NP tissues. However, in all categories, PPAR-γ ex-
pression was signiﬁcantly more extensive and intense in PC
and PIN tissues than in BPH and NP tissues, and PPAR-γ ex-
pression was higher in G3 cancer than in G1 cancer. Paltoo
et al. demonstrated that there were no signiﬁcant diﬀerences
between PPAR-γ expression in grades and stages [16]. Using
competitive PCR, these diﬀerences may be demonstrated in
the near future.
Next, we demonstrated that PPAR-γ ligands induced re-
duction of the viability in PC cells in the range of 5–40μM
by using MTT assay. Furthermore, we also demonstrated
that PC cells treated with PPAR-γ ligands could induce early
apoptosis and DNA fragmentation in PC cells. Subbarayan
et al. have also demonstrated similar results [17]. Several re-
ports support the eﬃcacy of PPAR-γ ligands in PC [16, 18].
We expect that additional research will be progressed.
Concerning about TC, we demonstrate stronger expres-
sionofPPAR-γ inalltissuetypesofTCthaninnormaltestic-
ular tissues by immunohistochemical staining and RT-PCR.
There were no signiﬁcant diﬀerences among 5 histopatho-
logic groups. We classiﬁed 2 categories (epithelial cells and
bloodvessels)inTCandNTtissues,andexaminedtheinten-
sity of PPAR-α,- β, and-γ expression. There were no signiﬁ-
cant diﬀerences in the intensity of PPAR-α,- β expression be-
tween all categories of TC and NT tissues. However, PPAR-γ
expression was signiﬁcantly more extensive and intense in all
categories of TC than in NT tissues. Next, we demonstrated
that PPAR-γ ligands induced the reduction of viability in TC
cells in the range of 5–40μM by MTT assay. Furthermore, we
also demonstrated that TC cells treated with PPAR-γ ligands
could induce early apoptosis and DNA fragmentation in TC
cells. However, no further data on TC and PPAR-γ have been
documented in other reports. We expect additional research
will be progressed.M. Matsuyama and R. Yoshimura 11
In summary, PPAR-γ expression was signiﬁcantly more
extensiveandintenseinmalignanttissuesthaninnormaltis-
sue, and PPAR-γ expression was higher in G3 cancer than in
G1 cancer. Furthermore, PPAR-γ ligands induced the reduc-
tion of malignant cell viability through apoptosis in vitro.
These results indicate that PPAR-γ participates in initiation
and promotion of tumorigenesis.
These results raise the possibility that PPAR-γ may play
roleinthepathogenesisandprogressionofPCandTC.While
it is diﬃcult at this time to use PPAR-γ ligands at a clinical
dose (relatively nontoxic therapeutic approach) as suppres-
sive cancer therapy, we strongly suggest that further research
mayconﬁrmPPAR-γ ligandsasanovelapproachtothetreat-
ment of PC and TC.
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